Receive 30% off all Monoclonal IHC antibodies with code "MONO-IHC-30"! Offer valid for US customers and available internationally through distributors.

LY2835219 free base

Overview
Catalog # bs-6668c-10mg
Product Name LY2835219 free base
Specifications
Storage Buffer Powder
Storage Condition Store in dry, dark place at -20C for 1 year.
Target
Product Information Molecular Weight: 506.59

Formula: C27 H32 F2 N8

CAS Number: 1231929-97-7

InChi Key: UZWDCWONPYILKI-UHFFFAOYSA-N

InChi: InChI=1S/C27H32F2N8/c1-5-35-8-10-36(11-9-35)16-19-6-7-24(30-14-19)33-27-31-15-22(29)25(34-27)20-12-21(28)26-23(13-20)37(17(2)3)18(4)32-26/h6-7,12-15,17H,5,8-11,16H2,1-4H3,(H,30,31,33,34)

Smiles: CC1=NC2=C(C=C(C=C2F)C2=NC(NC3C=CC(CN4CCN(CC4)CC)=CN=3)=NC=C2F)N1C(C)C

Purity: 98.0

Solubility: Soluble in DMSO, not in water

Appearance: Solid Power.

Shelf Life: 1.0 years
Description LY2835219 free base is orally available cyclin-dependent kinase (CDK) inhibitor that targets the CDK4 (cyclin D1) and CDK6 (cyclin D3) cell cycle pathway, with potential antineoplastic activity. LY2835219 inhibits CDK4 and CDK6 with low nanomolar potency. LY2835219 specifically inhibits CDK4 and 6, thereby inhibiting retinoblastoma (Rb) protein phosphorylation in early G1. Inhibition of Rb phosphorylation prevents CDK-mediated G1-S phase transition, thereby arresting the cell cycle in the G1 phase, suppressing DNA synthesis and inhibiting cancer cell growth.